Jennifer Nicole Clements
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Nicole Clements has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Diana Isaacs
Cleveland Clinic Endocrinology & Metabolism Institute, 10685 Carnegie Avenue
3 shared publicationsLisa T. Meade
Piedmont HealthCare Dept of Endocrinology, 142 Sherlock Dr., Statesville, NC 28625
3 shared publicationsSara (Mandy) Reece
Philadelphia College of Osteopathic Medicine School of Pharmacy, 625 Old Peachtree Road NW, Suwaneee, GA 30024
3 shared publicationsDebra J. Reid
School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Bouvé College of Health Sciences, Boston, MA 02115
2 shared publications- Diana Isaacs
12Cleveland Clinic, Cleveland, OH
2 shared publications Eileen D. Ward
Presbyterian College School of Pharmacy, 307 N. Broad St, Clinton, SC 29325
2 shared publications
Latest Publications
- 5 October 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- p. 1-4
Considerations and challenges in microdosing of GLP-1-based receptor agonists
1. GLP-1 RAs have rapidly evolved over two decades and since initial approval for type 2 diabetes. Recent guidelines from the American Association of Clinical Endocrinology, European Association fo...
- 5 October 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- p. 1-4
Considerations and challenges in microdosing of GLP-1-based receptor agonists
1. GLP-1 RAs have rapidly evolved over two decades and since initial approval for type 2 diabetes. Recent guidelines from the American Association of Clinical Endocrinology, European Association fo...
- Open Access
- 15 February 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (3) , e70119
Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy
Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing diabetic retinopathy. The American Academy of Ophthalmology classifies diabetic retinopathy into non‐proliferative diabetic retinopathy and proliferative diabetic retinopathy, distinguished by the absence or presence of neovascularization, respectively. Complications such as diabetic macular edema, retinal detachment, and irreversible vision loss further underscore the need for effective therapies. Current treatments include laser photocoagulation, vitrectomy, and anti‐vascular endothelial growth factor agents. This narrative review evaluates established pharmacotherapy and explores emerging therapies targeting novel pathways such as inflammation, oxidative stress, and vascular stability. Investigational agents, including integrin inhibitors, gene therapies, and small‐molecule antagonists, alongside innovative delivery systems such as topical formulations and sustained‐release implants, offer the potential to enhance treatment efficacy, patient adherence, and overall outcomes in diabetic retinopathy. By examining these advancements, including innovative delivery systems, this review aims to inform practitioners about the evolving landscape of pharmacotherapy for diabetic retinopathy.
- 15 February 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (3) , e70119
Open AccessCurrent and Emerging Pharmacologic Therapies for Diabetic Retinopathy
Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing diabetic retinopathy. The American Academy of Ophthalmology classifies diabetic retinopathy into non‐proliferative diabetic retinopathy and proliferative diabetic retinopathy, distinguished by the absence or presence of neovascularization, respectively. Complications such as diabetic macular edema, retinal detachment, and irreversible vision loss further underscore the need for effective therapies. Current treatments include laser photocoagulation, vitrectomy, and anti‐vascular endothelial growth factor agents. This narrative review evaluates established pharmacotherapy and explores emerging therapies targeting novel pathways such as inflammation, oxidative stress, and vascular stability. Investigational agents, including integrin inhibitors, gene therapies, and small‐molecule antagonists, alongside innovative delivery systems such as topical formulations and sustained‐release implants, offer the potential to enhance treatment efficacy, patient adherence, and overall outcomes in diabetic retinopathy. By examining these advancements, including innovative delivery systems, this review aims to inform practitioners about the evolving landscape of pharmacotherapy for diabetic retinopathy.
- Open Access
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-6
Incretin therapy and obesity: current and future pharmacologic possibilities
Obesity is a global epidemic, posing significant challenges to individual health and healthcare systems. This article explores the pharmacology of incretin-based therapies beyond single receptor agonists and focuses on their emerging role in obesity management. The complex interplay between metabolic, environmental, and psychosocial factors contributes to obesity and its wide-ranging clinical sequelae. Emphasis is placed on the physiological functions of key hormones, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), amylin, and glucagon, in regulating energy balance, appetite, and insulin secretion. The commentary discusses novel therapeutic approaches, including dual and triple receptor agonists. Future directions in personalized medicine are included to highlight innovative drug-delivery systems and potential new targets. Collectively, incretin-targeted therapies have the potential to be the next generation of obesity treatments, effective in achieving outcomes and tailored for individual patient needs.
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-6
Open AccessIncretin therapy and obesity: current and future pharmacologic possibilities
Obesity is a global epidemic, posing significant challenges to individual health and healthcare systems. This article explores the pharmacology of incretin-based therapies beyond single receptor agonists and focuses on their emerging role in obesity management. The complex interplay between metabolic, environmental, and psychosocial factors contributes to obesity and its wide-ranging clinical sequelae. Emphasis is placed on the physiological functions of key hormones, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), amylin, and glucagon, in regulating energy balance, appetite, and insulin secretion. The commentary discusses novel therapeutic approaches, including dual and triple receptor agonists. Future directions in personalized medicine are included to highlight innovative drug-delivery systems and potential new targets. Collectively, incretin-targeted therapies have the potential to be the next generation of obesity treatments, effective in achieving outcomes and tailored for individual patient needs.
- Open Access
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-8
Current clinical application of incretin therapy for obesity management
Incretin therapy, utilizing glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists, is a cornerstone of obesity management due to effects on appetite suppression, weight loss, and metabolic improvement. Liraglutide, semaglutide, and tirzepatide promote weight reduction by modulating incretin hormone pathways, leading to decreased caloric intake. Recent studies with semaglutide and tirzepatide have demonstrated substantial weight loss outcomes beyond glucose-lowering benefits, shifting the paradigm of obesity treatment toward pharmacological interventions. While effective in weight loss, challenges remain regarding long-term efficacy, tolerability, and accessibility. Future directions include optimizing combination therapies and exploring novel incretin-based molecules with dual or triple receptor activity. This review focuses on the clinical application of incretin therapy in obesity, emphasizing practical considerations and highlighting therapeutic benefits for obesity to improve outcomes and public health.
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-8
Open AccessCurrent clinical application of incretin therapy for obesity management
Incretin therapy, utilizing glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists, is a cornerstone of obesity management due to effects on appetite suppression, weight loss, and metabolic improvement. Liraglutide, semaglutide, and tirzepatide promote weight reduction by modulating incretin hormone pathways, leading to decreased caloric intake. Recent studies with semaglutide and tirzepatide have demonstrated substantial weight loss outcomes beyond glucose-lowering benefits, shifting the paradigm of obesity treatment toward pharmacological interventions. While effective in weight loss, challenges remain regarding long-term efficacy, tolerability, and accessibility. Future directions include optimizing combination therapies and exploring novel incretin-based molecules with dual or triple receptor activity. This review focuses on the clinical application of incretin therapy in obesity, emphasizing practical considerations and highlighting therapeutic benefits for obesity to improve outcomes and public health.
- Open Access
- 28 October 2025
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 21 (2) , 5-8
A Clinical Review of Continuous Glucose Monitoring in the Hospital Setting
Table 2: Challenges and limitations of continuous glucose monitors in the hospital with potential solutions
- 28 October 2025
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 21 (2) , 5-8
Open AccessA Clinical Review of Continuous Glucose Monitoring in the Hospital Setting
Table 2: Challenges and limitations of continuous glucose monitors in the hospital with potential solutions
- Open Access
- 11 September 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (10) , 1078-1093
The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
The popularity of incretin‐based therapies has increased substantially over the past several years due to their clinically significant efficacy for weight loss and positive impact on weight‐related comorbid conditions, yet, few clinical practice guidelines for the management of overweight and obesity have been updated to incorporate these agents. The increased demand for incretin‐based therapies for weight management has revealed barriers to their implementation related to cost, availability, and emerging safety concerns. This opinion paper aims to briefly review the available literature on the current role of incretin‐based therapy for chronic weight management in persons with overweight or obesity and provide recommendations for clinical pharmacists utilizing these agents. The intent of this opinion paper is to discuss the benefits and risks of incretin‐based therapy for weight management, review approaches for clinical pharmacists to overcome barriers to their implementation, and address ongoing questions related to their use. Finally, the authors suggest an approach to the management of people with overweight or obesity with incretin‐based therapy using the Pharmacists' Patient Care Process along with actions clinical pharmacists can take to ensure best practices with these agents.
- 11 September 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (10) , 1078-1093
Open AccessThe Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
The popularity of incretin‐based therapies has increased substantially over the past several years due to their clinically significant efficacy for weight loss and positive impact on weight‐related comorbid conditions, yet, few clinical practice guidelines for the management of overweight and obesity have been updated to incorporate these agents. The increased demand for incretin‐based therapies for weight management has revealed barriers to their implementation related to cost, availability, and emerging safety concerns. This opinion paper aims to briefly review the available literature on the current role of incretin‐based therapy for chronic weight management in persons with overweight or obesity and provide recommendations for clinical pharmacists utilizing these agents. The intent of this opinion paper is to discuss the benefits and risks of incretin‐based therapy for weight management, review approaches for clinical pharmacists to overcome barriers to their implementation, and address ongoing questions related to their use. Finally, the authors suggest an approach to the management of people with overweight or obesity with incretin‐based therapy using the Pharmacists' Patient Care Process along with actions clinical pharmacists can take to ensure best practices with these agents.
- 20 February 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (2) , 74-76
Pharmacists in diabetes management: Enhancing patient care through practice, education, and advocacy
- 20 February 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (2) , 74-76
Pharmacists in diabetes management: Enhancing patient care through practice, education, and advocacy
- 16 January 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (1) , 62-69
Teaching experiences in pharmacy residency
Postgraduate pharmacy residencies equip trainees with advanced clinical skills for patient care and prepare them for specialized roles in their careers. Teaching is a core responsibility for most pharmacists, yet postgraduate residency training often lacks standardization in teaching and learning experiences. The American Society of Health‐System Pharmacists (ASHP) provides residency accreditation standards; however, the activities related to teaching objectives may lack consistency across institutions and programs. The 2024 American College of Clinical Pharmacy (ACCP) Publications Committee updated a previous publication on standardized teaching experiences for all residencies and programs offering a teaching certificate or other teaching experiences. The current paper highlights information and activities for residency programs to promote diverse teaching experiences, including the introduction of a tier system. Postgraduate pharmacy residencies should adopt these guidelines to offer consistent teaching experiences with personalization for trainees. Residents should also inquire about the teaching components of programs to choose the best fit for their career goals. There should be a balance between standardization and flexibility in teaching experiences to prepare residents for diverse roles in clinical practice or academia.
- 16 January 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (1) , 62-69
Teaching experiences in pharmacy residency
Postgraduate pharmacy residencies equip trainees with advanced clinical skills for patient care and prepare them for specialized roles in their careers. Teaching is a core responsibility for most pharmacists, yet postgraduate residency training often lacks standardization in teaching and learning experiences. The American Society of Health‐System Pharmacists (ASHP) provides residency accreditation standards; however, the activities related to teaching objectives may lack consistency across institutions and programs. The 2024 American College of Clinical Pharmacy (ACCP) Publications Committee updated a previous publication on standardized teaching experiences for all residencies and programs offering a teaching certificate or other teaching experiences. The current paper highlights information and activities for residency programs to promote diverse teaching experiences, including the introduction of a tier system. Postgraduate pharmacy residencies should adopt these guidelines to offer consistent teaching experiences with personalization for trainees. Residents should also inquire about the teaching components of programs to choose the best fit for their career goals. There should be a balance between standardization and flexibility in teaching experiences to prepare residents for diverse roles in clinical practice or academia.
- 5 February 2024
- Published by American Diabetes Association in Diabetes Spectrum
- Vol. 37 (2) , 149-152
Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals
Background: Insulin is the treatment of choice for diabetes care in the hospital. There is some debate regarding the efficacy and safety of once-daily versus twice-daily insulin glargine in the hospital, particularly in the critically ill population. Objective: The purpose of this pilot study was to evaluate the efficacy and safety of insulin glargine administered as a once-daily versus twice-daily regimen in the noncritically ill population. Methods: A retrospective chart review was conducted from 1 June 2020 to 31 May 2021. Inclusion criteria were age ≥18 years and on a regimen of either once-daily or twice-daily insulin glargine for ≥72 hours during the specified time frame. The primary end point was a comparison of the number of days with all blood glucose measurements within the range of 70–180 mg/dL throughout a 24-hour period. Secondary end points included the number of hyperglycemic (>180 mg/dL) and hypoglycemic (<70 mg/dL) events that occurred in each study group. Results: Group 1 included 101 individuals who received once-daily dosing, and group 2 included 103 individuals who received twice-daily dosing. Baseline characteristics were similar between the groups except for a higher BMI at admission (P = 0.01) and a higher pre-admission A1C (P = 0.02) in group 2. No differences were found for the primary end point (P = 0.5) or for hypoglycemic (P = 0.6) or hyperglycemic (P = 0.7) events. Conclusion: There were no significant differences in efficacy or safety between once-daily and twice-daily insulin glargine in the noncritically ill population. A larger prospective study could confirm these results.
- 5 February 2024
- Published by American Diabetes Association in Diabetes Spectrum
- Vol. 37 (2) , 149-152
Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals
Background: Insulin is the treatment of choice for diabetes care in the hospital. There is some debate regarding the efficacy and safety of once-daily versus twice-daily insulin glargine in the hospital, particularly in the critically ill population. Objective: The purpose of this pilot study was to evaluate the efficacy and safety of insulin glargine administered as a once-daily versus twice-daily regimen in the noncritically ill population. Methods: A retrospective chart review was conducted from 1 June 2020 to 31 May 2021. Inclusion criteria were age ≥18 years and on a regimen of either once-daily or twice-daily insulin glargine for ≥72 hours during the specified time frame. The primary end point was a comparison of the number of days with all blood glucose measurements within the range of 70–180 mg/dL throughout a 24-hour period. Secondary end points included the number of hyperglycemic (>180 mg/dL) and hypoglycemic (<70 mg/dL) events that occurred in each study group. Results: Group 1 included 101 individuals who received once-daily dosing, and group 2 included 103 individuals who received twice-daily dosing. Baseline characteristics were similar between the groups except for a higher BMI at admission (P = 0.01) and a higher pre-admission A1C (P = 0.02) in group 2. No differences were found for the primary end point (P = 0.5) or for hypoglycemic (P = 0.6) or hyperglycemic (P = 0.7) events. Conclusion: There were no significant differences in efficacy or safety between once-daily and twice-daily insulin glargine in the noncritically ill population. A larger prospective study could confirm these results.
- 6 March 2023
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
Significant publications in diabetes pharmacotherapy and technology in 2020
The most significant articles on diabetes pharmacotherapy and technology in the peer-reviewed literature from 2020, as determined by a panel of pharmacists with expertise in diabetes care and education, are summarized. Members of the Association of Diabetes Care and Education Specialists Pharmacy Community of Interest were selected to review articles published in prominent peer-reviewed journals in 2020 that most impacted diabetes pharmacotherapy and technology. A list of 37 nominated articles were compiled (22 in diabetes pharmacotherapy and 15 in diabetes technology). Based on discussion among the authors, the articles were ranked based on significant contribution, impact, and diversity to diabetes pharmacotherapy and technology. The top 10 highest ranked publications (n=6 for diabetes pharmacotherapy and n=4 in diabetes technology) are summarized in this article. With the significant number of publications in diabetes care and education, it can be challenging and overwhelming to remain current with published literature. This review article may be helpful in identifying key articles in diabetes pharmacotherapy and technology from the year 2020.
- 6 March 2023
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
Significant publications in diabetes pharmacotherapy and technology in 2020
The most significant articles on diabetes pharmacotherapy and technology in the peer-reviewed literature from 2020, as determined by a panel of pharmacists with expertise in diabetes care and education, are summarized. Members of the Association of Diabetes Care and Education Specialists Pharmacy Community of Interest were selected to review articles published in prominent peer-reviewed journals in 2020 that most impacted diabetes pharmacotherapy and technology. A list of 37 nominated articles were compiled (22 in diabetes pharmacotherapy and 15 in diabetes technology). Based on discussion among the authors, the articles were ranked based on significant contribution, impact, and diversity to diabetes pharmacotherapy and technology. The top 10 highest ranked publications (n=6 for diabetes pharmacotherapy and n=4 in diabetes technology) are summarized in this article. With the significant number of publications in diabetes care and education, it can be challenging and overwhelming to remain current with published literature. This review article may be helpful in identifying key articles in diabetes pharmacotherapy and technology from the year 2020.